Bioherent — Seed (estimated) · €284K partial: only one investor's ticket was disclosed

Bioherent closed a co-investment round led by CDTI through its Innvierte programme, alongside Bullnet Capital III, SCR Pyme and ACE 53. The money will take its antibiotic-allergy diagnostic technology to the hospital market. €284K is CDTI's commitment, part of Innvierte's March 2026 batch of €113.62M. The sources don't give the round's total size.